Venture&Growth Archives - Gilde Healthcare

Menu
Menu
Home

Latest news

Latest news

Latest news
Venture&Growth

Latest news
Private Equity

Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000...

31 July 2025

Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000...

31 July 2025

Gilde Healthcare announces successful sale of its outsourced specialist care provider Novicare to Gimv

Gilde Healthcare, the specialized healthcare investor, has reached an agreement on the sale of its Dutch portfolio company Novicare to Gimv*. Novicare provides outsourced medical and paramedical (tele)care services. The...

28 August 2025

Gilde Healthcare announces successful sale of its outsourced specialist care provider Novicare to Gimv

Gilde Healthcare, the specialized healthcare investor, has reached an agreement on the sale of its Dutch portfolio company Novicare to Gimv*. Novicare provides outsourced medical and paramedical (tele)care services. The...

28 August 2025

Filter & search

Fund strategy:
  • All
  • Private Equity
  • Venture&Growth
Search:

Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering...

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. In addition,...
July 31, 2025

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for pr...

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary...
July 9, 2025

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Sta...

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007 in Stargardt disease   Funding will also advance a broader pipeline of genetic...
June 11, 2025

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance ...

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term management of glaucoma and other chronic ophthalmic diseases. Gilde Healthcare joined the...
June 3, 2025

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by An...

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8 is the only therapy considered medically necessary by the policy when the...
April 28, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Applicati...

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor payload activity Phase 1 clinical trial of TGW101 initiated; Company plans...
April 22, 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with...

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke has been appointed as new chair of the board of directors, reflecting...
April 1, 2025

Gilde Healthcare company SpliceBio announces first patient dosed in Phase 1/2 ASTRA study ...

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease   SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused...
March 13, 2025

Gilde Healthcare participates in $65 Million financing of Microtransponder to enhance Vivi...

MicroTransponder®, Inc, today announces a $65 million Series F financing round. MicroTransponder is a fast growing commercial stage stroke company with the FDA-approved Vivistim® Paired VNS™ System. Gilde Healthcare joins the round as new investor, together with Longitude Capital. Existing investors include US Venture Partners (USVP), Osage...
March 12, 2025
Loading...
These were all articles
c2e6a418e3